Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:CLIN
- CUSIP: N/A
- Web: www.clinigengroup.com/
- Market Cap: £1.13 billion
- Outstanding Shares: 114,900,000
- 50 Day Moving Avg: GBX 897.88
- 200 Day Moving Avg: GBX 843.88
- 52 Week Range: GBX 610.50 - GBX 995
Sales & Book Value:
- Trailing P/E Ratio: 78.64
- P/E Growth: 0.00
- Annual Revenue: £315.2 million
- Price / Sales: 3.58
- Book Value: GBX 2.08 per share
- Price / Book: 4.73
- EBIDTA: £59.8 million
- Net Margins: 1.98%
- Return on Equity: 2.18%
- Return on Assets: 1.15%
- Average Volume: 290,403 shs.
Frequently Asked Questions for Clinigen Group PLC (LON:CLIN)
What is Clinigen Group PLC's stock symbol?
Clinigen Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."
How often does Clinigen Group PLC pay dividends? What is the dividend yield for Clinigen Group PLC?
Clinigen Group PLC announced a dividend on Wednesday, March 15th. Investors of record on Thursday, March 23rd will be paid a dividend of GBX 1.60 per share on Thursday, April 13th. This represents a dividend yield of 0.2%. The ex-dividend date is Thursday, March 23rd. The official announcement can be accessed at this link. View Clinigen Group PLC's Dividend History.
When will Clinigen Group PLC make its next earnings announcement?
Where is Clinigen Group PLC's stock going? Where will Clinigen Group PLC's stock price be in 2017?
4 analysts have issued 1 year target prices for Clinigen Group PLC's shares. Their forecasts range from GBX 895 to GBX 1,200. On average, they expect Clinigen Group PLC's share price to reach GBX 1,041.25 in the next year. View Analyst Ratings for Clinigen Group PLC.
Who are some of Clinigen Group PLC's key competitors?
Some companies that are related to Clinigen Group PLC include Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR), Array BioPharma (ARRY), Acceleron Pharma (XLRN), Dermira (DERM), Xencor (XNCR), Amarin Corporation PLC (AMRN), Insmed (INSM), Acorda Therapeutics (ACOR), Forward Pharma A/S (FWP), NeuroDerm (NDRM), Omeros Corporation (OMER) and Aduro Biotech (ADRO).
Who are Clinigen Group PLC's key executives?
Clinigen Group PLC's management team includes the folowing people:
- Shaun Edward Chilton, Chief Executive Officer, Director
- Martin James Abell, Chief Financial Officer - Elect, Director
- Peter Vance Allen, Independent Non-Executive Chairman of the Board
- John Bacon, Non-Executive Director
- Peter Lutz George, Non-Executive Director
- John Hartup, Independent Non-Executive Director
- Ian J. Nicholson, Independent Non-Executive Director
How do I buy Clinigen Group PLC stock?
Shares of Clinigen Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Clinigen Group PLC's stock price today?
MarketBeat Community Rating for Clinigen Group PLC (LON CLIN)MarketBeat's community ratings are surveys of what our community members think about Clinigen Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Clinigen Group PLC stock can currently be purchased for approximately GBX 983.
Consensus Ratings for Clinigen Group PLC (LON:CLIN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 3 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||GBX 1,041.25|
Analysts' Ratings History for Clinigen Group PLC (LON:CLIN)
(Data available from 7/27/2015 forward)
|7/18/2017||Numis Securities Ltd||Downgrade||Add||GBX 1,100|
|7/7/2017||Peel Hunt||Boost Price Target||Buy||GBX 1,015 -> GBX 1,200|
|5/22/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 970|
|4/13/2017||N+1 Singer||Reiterated Rating||Buy||GBX 895|
|1/20/2016||Royal Bank Of Canada||Lower Price Target||Outperform||GBX 770 -> GBX 750|
Earnings History for Clinigen Group PLC (LON:CLIN)Earnings History by Quarter for Clinigen Group PLC (LON CLIN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Clinigen Group PLC (LON:CLIN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History by Quarter for Clinigen Group PLC (LON CLIN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Clinigen Group PLC (LON:CLIN)Insider Trades by Quarter for Clinigen Group PLC (LON:CLIN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/28/2017||John Bacon||Insider||Sell||200,000||GBX 843||£1,686,000|
|6/22/2017||Peter George||former CEO||Sell||500,000||GBX 875||£4,375,000|
|11/11/2016||John Bacon||Insider||Sell||200,000||GBX 717||£1,434,000|
|10/18/2016||Shaun Edward Chilton||Insider||Sell||97,246||GBX 750||£729,345|
|10/7/2015||Edward Chilton,Shaun||Insider||Sell||412,778||GBX 685||£2,827,529.30|
|6/3/2015||John Hartup||Insider||Sell||23,934||GBX 644||£154,134.96|
Headline Trends for Clinigen Group PLC (LON:CLIN)
Latest Headlines for Clinigen Group PLC (LON:CLIN)
|Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular ... - GlobeNewswire (press release)|
globenewswire.com - July 21 at 11:47 PM
|Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular ... - Nasdaq|
www.nasdaq.com - July 20 at 4:28 AM
|Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping|
finance.yahoo.com - July 19 at 6:27 PM
|Clinigen and Sarepta Therapeutics launch a Managed Access Program to treat patients with Duchenne Muscular Dystrophy amenable to exon 51 skipping|
finance.yahoo.com - July 19 at 6:27 PM
|Clinigen Group Reports "Excellent" Annual Performance In All Units|
www.morningstar.co.uk - July 18 at 6:46 PM
|Clinigen Group plc: Year End Trading Update|
finance.yahoo.com - July 18 at 3:44 AM
|Clinigen Group Plc: Leads amongst peers with strong fundamentals|
finance.yahoo.com - July 10 at 5:15 PM
|Clinigen Group PLC (LON:CLIN) Price Target Increased to GBX 1,200 by Analysts at Peel Hunt|
www.americanbankingnews.com - July 8 at 10:04 AM
|Clinigen Group PLC (CLIN) Insider Sells £1,686,000 in Stock|
www.americanbankingnews.com - June 30 at 2:09 PM
|Clinigen Group PLC (CLIN) Insider Peter Allen Sells 500,000 Shares|
www.americanbankingnews.com - June 26 at 7:40 AM
|CORRECTING AND REPLACING: Clinigen Signs Exclusive Supply Agreements in Global Access With Mitsubishi ... - Business Wire (press release)|
www.businesswire.com - June 22 at 9:39 PM
|CORRECTING AND REPLACING: Clinigen Signs Exclusive Supply Agreements in Global Access With Mitsubishi Tanabe, Shionogi and Romark|
finance.yahoo.com - June 22 at 4:38 PM
|Clinigen Signs Exclusive Supply Agreements in Global Access With Mitsubishi Tanabe, Shionogi and Romark|
finance.yahoo.com - June 21 at 3:02 AM
|Clinigen Wins Support To Change Cardioxane Information In Europe|
www.morningstar.co.uk - May 23 at 12:46 PM
|Stifel Nicolaus Reiterates "Buy" Rating for Clinigen Group PLC (CLIN)|
www.americanbankingnews.com - May 22 at 5:02 PM
|Clinigen Group PLC's (CLIN) Buy Rating Reiterated at Numis Securities Ltd|
www.americanbankingnews.com - May 22 at 4:28 PM
|TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent ... - Nasdaq|
www.nasdaq.com - May 11 at 10:01 PM
|Clinigen Launches Managed Access Programme For Niraparib In Europe|
www.morningstar.co.uk - May 11 at 4:59 PM
|TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer|
finance.yahoo.com - May 11 at 2:36 AM
|EQS-News: European Mediscience Awards 2017 Shortlist announced|
www.finanznachrichten.de - May 10 at 4:33 PM
|Clinigen Group Plc – Value Analysis (LONDON:CLIN) : April 26, 2017|
finance.yahoo.com - April 26 at 5:03 PM
|Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell ... - GlobeNewswire (press release)|
globenewswire.com - April 25 at 4:10 PM
|Clinigen Group Plc breached its 50 day moving average in a Bullish Manner : CLIN-GB : April 25, 2017|
finance.yahoo.com - April 25 at 12:13 PM
|Peel Hunt Reaffirms "Buy" Rating for Clinigen Group PLC (CLIN)|
www.americanbankingnews.com - April 25 at 7:07 AM
|Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)|
finance.yahoo.com - April 24 at 4:15 PM
|N+1 Singer Reiterates Buy Rating for Clinigen Group PLC (CLIN)|
www.americanbankingnews.com - April 13 at 2:42 PM
|Clinigen Group PLC's (CLIN) Buy Rating Reaffirmed at Stifel Nicolaus|
www.americanbankingnews.com - April 8 at 6:08 PM
|Clinigen Group Plc : CLIN-GB: Dividend Analysis : March 24th, 2017 (record date) : By the numbers : April 4, 2017|
finance.yahoo.com - April 7 at 9:00 AM
|Clinigen Group PLC (CLIN) Upgraded to Buy at Numis Securities Ltd|
www.americanbankingnews.com - April 4 at 1:18 PM
|Clinigen Group plc: Strong H1 Performance with Adjusted EPS up 31%* - Business Wire (press release)|
www.businesswire.com - March 16 at 5:39 PM
|Half Year 2017 Clinigen Group PLC Earnings Release - Before Market Open|
biz.yahoo.com - March 15 at 4:43 PM
|Clinigen Group plc: Strong H1 Performance with Adjusted EPS up 31%*|
uk.finance.yahoo.com - March 15 at 6:41 AM
|Clinigen Group PLC (CLIN) Earns Buy Rating from Numis Securities Ltd|
www.americanbankingnews.com - March 10 at 7:37 PM
|Clinigen Gets Approval To Launch Perampanel In South Africa|
www.morningstar.co.uk - March 10 at 9:17 AM
|Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer|
www.nasdaq.com - January 17 at 9:00 AM
|Clinigen Group Gives Exclusive US Licence For Totect To Cumberland|
www.morningstar.co.uk - January 10 at 3:29 AM
|Cumberland Pharmaceuticals and Clinigen Enter Exclusive U.S. Commercialization Agreement For Totect®|
finance.yahoo.com - January 9 at 5:28 PM
|Wasatch Invests in 7 New Holdings|
finance.yahoo.com - December 12 at 9:39 PM
Clinigen Group PLC (CLIN) Chart for Thursday, July, 27, 2017